Human Papillomavirus Vaccination: Expected Impacts and Unresolved Issues
In 2006, the US Food and Drug Administration licensed the first vaccine against human papillomavirus (HPV), Gardasil (Merck & Co). A second HPV vaccine, Cervarix (GlaxoSmithKline), is expected to be licensed in the near future. HPV vaccines present an exciting and unique opportunity for pediatricians to prevent cervical, and possibly other, HPV-associated cancers through vaccination. This review will focus on the quadrivalent HPV vaccine currently available in the United States, Gardasil, will describe the potential clinical and financial impacts of widespread vaccination with the vaccine, and will highlight some of the unresolved issues related to national vaccine implementation.
Abbreviations: GBS, Guillan-Barré syndrome, HPV, Human papillomavirus
To access this article, please choose from the options below
PII: S0022-3476(07)00955-9
doi:10.1016/j.jpeds.2007.09.052
© 2008 Mosby, Inc. All rights reserved.
